Prostat Biyopsisi Öncesinde Benign Ve Malign Patolojileri Ayırmada Nötrofil Lenfosit Oranı, Trombosit Lenfosit Oranı Ve Kırmızı Hücre Dağılım Genişiliği Parametreleri Kullanılabilir Mi?

Yıl 2022, Cilt: 44 Sayı: 4, 563 - 568, 19.07.2022

Abdullah Gürel

https://doi.org/10.20515/otd.1055020

Öz

Nötrofil lenfosit oranı (NLR), trombosit lenfosit oranı (PLR) ve kırmızı hücre dağılım genişliği (RDW) inflamatuar hastalıklar ve kanserler için önemli bir belirteçtir. Çalışmamızda NLR, PLR, RDW’nin prostat biyopsi kararı almada belirleyici olup olmadığı değerlendirildi. 2017 Mayıs ile 2019 Aralık tarihleri arasında prostat spesifik antijen (PSA) yüksekliği olması veya prostat muayenesinde bulgular olması nedeniyle transrektal ultrasonografi (TRUS) eşliğinde prostat biyopsisi yapılan hastaların patoloji sonuçları ve labaratuvar değerleri retrospektif olarak incelendi. Kontrol grubu olarak prostatla ilgili şikayeti olmayan ve inflamatuar hastalık öyküsü ve kanser tanısı olmayan kişiler alındı. Biyopsi sonucu benign ve prostat kanseri (Pca) gelen hastalar ve kontrol grubu arasında NLR, PLR ve RDW açısından farklılık olup olmadığı incelendi. Biyopsi yapılan hastalar benign ve Pca olarak karşılaştırıldığında; prostat spesifik antijen (PSA) ve yaşın Pca grubunda istatistiksel olarak yüksek olduğu, hemoglobin değerinin ise düşük olduğu görüldü. NLR, PLR ve RDW açısından gruplar arasında farklılık olmadığı görüldü. Kontrol grubu ile Pca grubu karşılaştırıldığında NLR ve RDW değerlerinin Pca grubunda istatistiksel olarak daha yüksek olduğu görüldü. Prostat biyopsisi yapılan hastalarda Pca veya benign nedenlere bağlı inflamatuar bir durum mevcuttur. İnflamatuar belirteçler olan NLR, PLR ve RDW ‘nin prostat biyopsisi öncesinde Pca ve benign ayrımı açısından belirteç olarak kullanılamayacağı saptandı. Kontrol grubu ile Pca arasında olan farkın ise kansere bağlı meydana gelen inflamasyona bağlı olduğu düşünüldü.

Anahtar Kelimeler

Prostat biyopsi, NLR, PLR, RDW, İnflamatuar biyomarker

Destekleyen Kurum

Yok

Proje Numarası

Yok

Teşekkür

Yok.

Can Neutrophil Lymphocyte Ratio, Platelet Lymphocyte Ratio and Red Cell Distribution Width Parameters Be Used To Differentiate Benign and Malignant Pathologies Before Prostate Biopsy?

Öz

Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and red cell distribution width (RDW) are important markers for inflammatory diseases and cancers. In our study, it was evaluated whether NLR, PLR, RDW were determinative for prostate biopsy decision. The pathology results and laboratory values of the patients who underwent transrectal ultrasonography (TRUS)-guided prostate biopsy between May 2017 and December 2019 due to elevated prostate specific antigen (PSA) or findings in prostate examination were analyzed retrospectively. People who had no prostate-related complaints, cancer diagnosis and no history of inflammatory disease were included as the control group. It was investigated whether there was a difference in NLR, PLR and RDW between the patients with benign prostate cancer (Pca) biopsy and the control group. When the biopsy patients were compared as benign and PCa; Prostate specific antigen (PSA) and age were found to be statistically higher in the Pca group, while the hemoglobin value was lower. There was no difference between the groups in terms of NLR, PLR and RDW. When the control group and the Pca group were compared, it was observed that the NLR and RDW values were statistically higher in the Pca group. Patients who underwent prostate biopsy have an inflammatory condition due to PCa or benign causes. It was determined that NLR, PLR and RDW, which are inflammatory markers, cannot be used as markers for the differentiation of PCa and benign before prostate biopsy. The difference between the control group and PCa was thought to be due to cancer-related inflammation. 

Anahtar Kelimeler

Prostate biopsy, NLR, PLR, RDW, Inflammatory biomarker

Proje Numarası

Yok

Kaynakça

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018;68:394-424.
• Wang MC, Valenzuela LA, Murphy GP, et al. Purification of a human prostate specific antigen. Investigative urology 1979;17:159-163.
• National Collaborating Centre for C. National Institute for Health and Care Excellence: Clinical Guidelines. Suspected Cancer: Recognition and Referral. London, National Institute for Health and Care Excellence (NICE)
• Hodge KK, McNeal JE, Stamey TA. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 1989;142:66-70.
• Lomas DJ, Ahmed HU. All change in the prostate cancer diagnostic pathway. Nature reviews Clinical oncology 2020;17:372-381.
• Schröder FH, Hugosson J, Roobol MJ,et al. Screening and prostate-cancer mortality in a randomized European study. The New England journal of medicine 2009;360:1320-1328.
• Loeb S, Bjurlin MA, Nicholson J,et al. Overdiagnosis and overtreatment of prostate cancer. European urology 2014;65:1046-1055.
• Serefoglu EC, Altinova S, Ugras NS, et al. How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer? Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2013;7:E293-298.
• Kesch C, Schütz V, Dieffenbacher S, et al. Multiparametric MRI fusion-guided biopsy for the diagnosis of prostate cancer. Current opinion in urology 2018;28:172-177.
• Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Williston Park, NY) 2002;16:217-226, 229; discussion 230-212.
• Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology 2012;60:199-215.
• Haverkamp J, Charbonneau B, Ratliff TL. Prostate inflammation and its potential impact on prostate cancer: a current review. Journal of cellular biochemistry 2008;103:1344-1353.
• Gu X, Gao X, Li X, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients. Scientific reports 2016;6:22089.
• Wang J, Zhou X, He Y,et al. Prognostic role of platelet to lymphocyte ratio in prostate cancer: A meta-analysis. Medicine (Baltimore) 2018;97:e12504.
• Huang TB, Zhu LY, Zhou GC,et al. Pre-treatment red blood cell distribution width as a predictor of clinically significant prostate cancer. International urology and nephrology 2021;53:1765-1771.
• Albayrak S, Zengin K, Tanik S, et al. Red cell distribution width as a predictor of prostate cancer progression. Asian Pacific journal of cancer prevention : APJCP 2014;15:7781-7784.
• Sciarra A, Gentilucci A, Salciccia S,et al. Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review. Journal of inflammation (London, England) 2016;13:35.
• Bardan R, Dumache R, Dema A, et al. The role of prostatic inflammation biomarkers in the diagnosis of prostate diseases. Clinical biochemistry 2014;47:909-915.
• Omer A, Lamb AD. Optimizing prostate biopsy techniques. Current opinion in urology 2019;29:578-586.
• Kawahara T, Fukui S, Sakamaki K,et al. Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. Oncotarget 2015;6:32169-32176.
• Yuksel OH, Urkmez A, Akan S, et al. Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer. Asian Pacific journal of cancer prevention : APJCP 2015;16:6407-6412.
• Deniz ME, Erçil H, Alma E, ve ark. Prostat Kanseri Tanısında Kan Nötrofil/Lenfosit Dağılımının Yeri. The New Journal of Urology 2020;15: 66-74.
• Tanik S, Albayrak S, Zengin K, et al. Is the neutrophil-lymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia? Asian Pacific journal of cancer prevention : APJCP 2014;15:6375-6379.
• Sun Z, Ju Y, Han F, et al. Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer. Journal of clinical laboratory analysis 2018;32.